These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 20636828)

  • 1. Objective radiological disease control with sandostatin monotherapy in metastatic neuroendocrine tumours.
    Khasraw M; Townsend A; Price T; Hart J; Bell D; Pavlakis N
    Intern Med J; 2010 Jun; 40(6):453-8. PubMed ID: 20636828
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of octreotide long-acting repeatable in neuroendocrine tumors: RADIANT-2 placebo arm post hoc analysis.
    Strosberg JR; Yao JC; Bajetta E; Aout M; Bakker B; Hainsworth JD; Ruszniewski PB; Van Cutsem E; Öberg K; Pavel ME
    Endocr Relat Cancer; 2015 Dec; 22(6):933-40. PubMed ID: 26373569
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group.
    Rinke A; Müller HH; Schade-Brittinger C; Klose KJ; Barth P; Wied M; Mayer C; Aminossadati B; Pape UF; Bläker M; Harder J; Arnold C; Gress T; Arnold R;
    J Clin Oncol; 2009 Oct; 27(28):4656-63. PubMed ID: 19704057
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogues according to Ki67 index in neuroendocrine tumours: an observational retrospective-prospective analysis from real life.
    Faggiano A; Carratù AC; Guadagno E; Tafuto S; Tatangelo F; Riccardi F; Mocerino C; Palmieri G; Damiano V; Siciliano R; Leo S; Mauro A; Tozzi LF; Battista C; De Rosa G; Colao A
    Oncotarget; 2016 Feb; 7(5):5538-47. PubMed ID: 26701729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of antiproliferative activity of octreotide LAR as first-line therapy for advanced neuroendocrine tumours.
    Laskaratos FM; Walker M; Naik K; Maragkoudakis E; Oikonomopoulos N; Grant L; Meyer T; Caplin M; Toumpanakis C
    Br J Cancer; 2016 Nov; 115(11):1321-1327. PubMed ID: 27811856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. INITIATION OF PATIENTS ONTO LONG-ACTING SOMATOSTATIN ANALOGUE THERAPY FOR NEUROENDOCRINE TUMORS: A SINGLE-CENTER REVIEW OF PRACTICE.
    Tadman M; Charlton P; Jafar-Mohammadi B; Talbot D; Grossman AB
    Endocr Pract; 2018 Feb; 24(2):189-194. PubMed ID: 29466059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients with Metastatic Neuroendocrine Midgut Tumors (PROMID): Results of Long-Term Survival.
    Rinke A; Wittenberg M; Schade-Brittinger C; Aminossadati B; Ronicke E; Gress TM; Müller HH; Arnold R;
    Neuroendocrinology; 2017; 104(1):26-32. PubMed ID: 26731483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neuroendocrine tumours - Medical therapy: Biological.
    Rinke A; Krug S
    Best Pract Res Clin Endocrinol Metab; 2016 Jan; 30(1):79-91. PubMed ID: 26971845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors.
    Al-Efraij K; Aljama MA; Kennecke HF
    Cancer Med; 2015 Jun; 4(6):864-70. PubMed ID: 25727756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy of somatostatin analogues in the treatment of neuroendocrine tumours based on the results of recent clinical trials].
    Igaz P
    Orv Hetil; 2014 Nov; 155(48):1908-12. PubMed ID: 25417137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating the characteristics and the management of patients with neuroendocrine tumors receiving octreotide LAR during a 6-year period.
    Anthony L; Vinik AI
    Pancreas; 2011 Oct; 40(7):987-94. PubMed ID: 21697761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term results of patients with malignant carcinoid syndrome receiving octreotide LAR.
    Toumpanakis C; Garland J; Marelli L; Srirajaskanthan R; Soh J; Davies P; Buscombe J; Caplin ME
    Aliment Pharmacol Ther; 2009 Oct; 30(7):733-40. PubMed ID: 19573169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Octreotide LAR Dosage and Survival Among Elderly Patients With Distant-Stage Neuroendocrine Tumors.
    Shen C; Xu Y; Dasari A; Shih YC; Yao JC
    Oncologist; 2016 Mar; 21(3):308-13. PubMed ID: 26911407
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of long-acting octreotide in patients with early-stage MEN1-related duodeno-pancreatic neuroendocrine tumours.
    Ramundo V; Del Prete M; Marotta V; Marciello F; Camera L; Napolitano V; De Luca L; Circelli L; Colantuoni V; Di Sarno A; Carratù AC; de Luca di Roseto C; Colao A; Faggiano A;
    Clin Endocrinol (Oxf); 2014 Jun; 80(6):850-5. PubMed ID: 24443791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of octreotide long-acting release on tumour growth control as a first-line treatment in neuroendocrine tumours of pancreatic origin.
    Jann H; Denecke T; Koch M; Pape UF; Wiedenmann B; Pavel M
    Neuroendocrinology; 2013; 98(2):137-43. PubMed ID: 23797176
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Somatostatin analogues in treatment of gastrointestinal and pancreatic neuroendocrine tumors].
    Simonenko VB; Dulin PA; Makanin MA
    Klin Med (Mosk); 2006; 84(4):4-8. PubMed ID: 16755846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Efficacy of somatostatin analogs in the treatment of neuroendocrine tumours and paraneoplastic syndromes].
    Sperlongano P; De Falco M; Pisaniello D; Parmeggiani D; Parmeggiani U
    Minerva Endocrinol; 2001 Dec; 26(4):293-5. PubMed ID: 11782719
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose octreotide acetate for management of gastroenteropancreatic neuroendocrine tumors.
    Chadha MK; Lombardo J; Mashtare T; Wilding GE; Litwin A; Raczyk C; Gibbs JF; Kuvshinoff B; Javle MM; Iyer RV
    Anticancer Res; 2009 Oct; 29(10):4127-30. PubMed ID: 19846960
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.